Literature DB >> 2488104

Pharmacokinetic and pharmacodynamic comparison of conventional and controlled release formulations of metoprolol [correction of motoprolol] in healthy Chinese subjects.

Y T Lee1, C S Liau, E C Wong, W J Chen, M F Chen, C C Chen.   

Abstract

A double-blind, crossover comparison of the pharmacokinetics and pharmacodynamics of controlled-release metoprolol (CR) 100 mg and 200 mg, metoprolol plain tablet 100 mg, metoprolol Durules 200 mg, and placebo was carried out in 10 healthy Chinese subjects. Standardized treadmill exercise tests according to the Bruce protocol were performed at a steady state of medication, before and 2, 6, 12, and 24 hours after the dose, and multiple blood samples were collected for determination of the metoprolol concentration. The plasma metoprolol levels over 24 hours were more uniform after metoprolol CR than Durules and the plain tablet. The mean peak concentrations for CR 100 mg, 200 mg, Durules, and the plain tablets were 231, 426, 790, and 1105 nmol/l, respectively. The corresponding fluctuation incides were 1.1, 1.5, 2.2, and 5.0. The effects on exercise heart rate (EHR) were investigated at steady state. Metoprolol CR produced more even reduction in EHR over 24 hours than Durules and plain tablets. All four treatments gave similar maximal reduction in EHR of about 20% at 2 hours after the dose. In conclusion, once daily metoprolol CR showed almost even blood levels and provided relatively constant levels of beta1 blockade over 24 hours in healthy Chinese subjects.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2488104     DOI: 10.1007/bf01865512

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  16 in total

1.  Quality of life after myocardial infarction: effect of long term metoprolol on mortality and morbidity.

Authors:  G Olsson; J Lubsen; G A van Es; N Rehnqvist
Journal:  Br Med J (Clin Res Ed)       Date:  1986-06-07

2.  Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study.

Authors:  J Wikstrand; I Warnold; G Olsson; J Tuomilehto; D Elmfeldt; G Berglund
Journal:  JAMA       Date:  1988-04-01       Impact factor: 56.272

3.  Plasma levels and pharmacological effects of metoprolol administered as controlled release (Durules) and ordinary tablets in healthy volunteers.

Authors:  G Johnsson; L Jordö; P Lundborg; C G Regårdh; O Rönn
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1980-07

4.  The antianginal efficacy and tolerability of controlled-release metoprolol once daily: a comparison with conventional metoprolol tablets twice daily.

Authors:  K Egstrup; T Gundersen; R Härkönen; E Karlsson; B Lundgren
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

5.  Efficacy and tolerability of a new controlled-release formulation of metoprolol: a comparison with conventional metoprolol tablets in mild to moderate hypertension.

Authors:  J J Houtzagers; J G Smilde; G Creytens; G Westergren
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

6.  Pharmacokinetics and pharmacodynamics of controlled-release metoprolol: a comparison with atenolol.

Authors:  I Blomqvist; G Westergren; A Sandberg; U E Jonsson; P Lundborg
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

7.  Design of a new multiple-unit controlled-release formulation of metoprolol--metoprolol CR.

Authors:  A Sandberg; G Ragnarsson; U E Jonsson; J Sjögren
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

8.  Pharmacokinetic and pharmacodynamic comparison of a new controlled-release formulation of metoprolol with a traditional slow-release formulation.

Authors:  B Oosterhuis; J H Jonkman; F A Kerkhof
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

9.  Long-term treatment with metoprolol after myocardial infarction: effect on 3 year mortality and morbidity.

Authors:  G Olsson; N Rehnqvist; A Sjögren; L Erhardt; T Lundman
Journal:  J Am Coll Cardiol       Date:  1985-06       Impact factor: 24.094

10.  Duration of action of beta blockers.

Authors:  S R Johansson; M McCall; C Wilhelmsson; J A Vedin
Journal:  Clin Pharmacol Ther       Date:  1980-05       Impact factor: 6.875

View more
  5 in total

Review 1.  Pharmacokinetic Variability of Drugs Used for Prophylactic Treatment of Migraine.

Authors:  Peer Tfelt-Hansen; Frederik Nybye Ågesen; Agniezka Pavbro; Jacob Tfelt-Hansen
Journal:  CNS Drugs       Date:  2017-05       Impact factor: 5.749

Review 2.  Metoprolol: a pharmacoeconomic and quality-of-life evaluation of its use in hypertension, post-myocardial infarction and dilated cardiomyopathy.

Authors:  D H Peters; P Benfield
Journal:  Pharmacoeconomics       Date:  1994-10       Impact factor: 4.981

3.  A double-blind comparison of once-daily metoprolol controlled-release and atenolol in the treatment of Chinese patients with mild to moderate hypertension.

Authors:  M F Chen; C Y Yang; W J Chen; C M Lee; C C Wu; C S Liau; Y T Lee
Journal:  Cardiovasc Drugs Ther       Date:  1995-06       Impact factor: 3.727

Review 4.  Controlled release metoprolol formulations. A review of their pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and ischaemic heart disease.

Authors:  G L Plosker; S P Clissold
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

5.  Receptor binding assays in analysing the bioavailability and pharmacodynamic bioequivalence of active drug moieties. A study of metoprolol.

Authors:  T Kaila; L Roivas; P J Neuvonen
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.